

TRANSMITTAL LETTER TO THE UNITED STATES

DESIGNATED/ELECTED OFFICE (DO/EO/US)

CONCERNING A FILING UNDER 35 U.S.C. 371

219277US0PCT

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

10/049937

INTERNATIONAL APPLICATION NO.

PCT/JP00/05522

INTERNATIONAL FILING DATE

18 AUGUST 2000

PRIORITY DATE CLAIMED

23 AUGUST 1999

TITLE OF INVENTION

SUBSTITUTED BENZYLTHLAZOLIDINE-2, 4-DIONE DERIVATIVES

APPLICANT(S) FOR DO/EO/US

Masahiro NOMURA, et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
  - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
  - b. ☒ has been communicated by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
  - a. ☒ is attached hereto.
  - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
  - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ have been communicated by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11. ☐ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☒ A copy of the International Search Report (PCT/ISA/210).

Items 13 to 20 below concern document(s) or information included:

13. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☐ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
20. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
21. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
22. ☐ Certificate of Mailing by Express Mail
23. ☒ Other items or information:

Notice of Priority / PTO-1449

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

INTERNATIONAL APPLICATION NO.

ATTORNEY'S DOCKET NUMBER

10/049937

PCT/JP00/05522

219277US0PCT

24. The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :

- ☐ Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO ..... \$1040.00
- ☒ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... \$890.00
- ☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$740.00
- ☐ International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... \$710.00
- ☐ International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) ..... \$100.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

\$890.00

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).

\$0.00

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	12 - 20 =	0	x \$18.00	\$0.00
Independent claims	4 - 3 =	1	x \$84.00	\$84.00
Multiple Dependent Claims (check if applicable).			<input type="checkbox"/>	\$0.00

TOTAL OF ABOVE CALCULATIONS =

\$974.00

☐ Applicant claims small entity status. See 37 CFR 1.27). The fees indicated above are reduced by 1/2.

\$0.00

SUBTOTAL =

\$974.00

Processing fee of \$130.00 for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).

\$0.00

TOTAL NATIONAL FEE =

\$974.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).

\$0.00

TOTAL FEES ENCLOSED =

\$974.00

Amount to be refunded \$  
charged \$

- a. ☒ A check in the amount of \$974.00 to cover the above fees is enclosed.
- b. ☐ Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \_\_\_\_\_ to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 15-0030 A duplicate copy of this sheet is enclosed.
- d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:



22850

(703) 413-0000

Surinder Sachar  
Registration No. 34,423

SIGNATURE

Norman F. Oblon

NAME

24,618

REGISTRATION NUMBER

DATE

Feb. 20 2002

## SPECIFICATION

## Title of the invention

Substituted benzylthiazolidine-2,4-dione derivativesTechnical field

The present invention relates to substituted benzylthiazolidine-2,4-dione derivatives effective for the prevention and/or therapy of metabolic diseases such as diabetes and hyperlipidemia as agonists of peroxisome proliferator-activated receptor (abbreviated as PPAR) being nuclear receptor, in particular, as agonists of human PPAR, their addition salts, process for preparing them, and medicinal compositions containing these compounds.

## Background technologies

The peroxisome proliferator-activated receptor (PPAR) is a ligand-dependent transcription factor that belongs to nuclear receptor superfamily similarly to steroid receptor, retinoid receptor, thyroid receptor, etc., and three isoforms ( $\alpha$  type,  $\beta$  (or  $\delta$ ) type and  $\gamma$  type) with different histological distribution have been identified hitherto in human and various animal species (Proc. Natl. Acad. Sci., 1992, 89, 4653). Thereamong, the PPAR $\alpha$  is distributed in the liver, kidney, etc. with high catabolic capacity for fatty acids and, particularly high expression is recognized in the liver, (Endo-crinology, 1995, 137, 354), positively or negatively controlling the expressions of genes related to the metabolism and the intracellular transport of fatty acids (e.g. acyl CoA synthetic enzyme, fatty acid-binding protein and lipoprotein lipase) and apolipoprotein (AI, AII, CIII) genes related to the metabolisms of cholesterol and neutral lipid. The PPAR $\beta$  is expressed ubiquitously in the tissues or organisms centering

around nerve cells. At present, the physiological significance of PPAR $\beta$  is unclear. The PPAR $\gamma$  is highly expressed in the adipocytes and contributed to the differentiation of adipocytes (J. Lipid Res., 1996, 37, 907). In this way, each isoform of PPAR play specific functions in the particular organs and tissues.

Moreover, it is reported that a knock-out mouse of PPAR $\alpha$  exhibits hypertriglyceridemia with ageing and becomes obesity mainly by increasing the white adipocytes (J. Biol. Chem., 1998, 273, 29577), hence the relevance between activation of PPAR $\alpha$  and decreasing action of lipids (cholesterol and triglyceride) in blood is suggested strongly.

On the other hand, fibrates and statins are widely used so far as the therapeutic drugs for hyperlipidemia. However, the fibrates have only weak decreasing action of cholesterol, while the statins have weak decreasing action of free fatty acids and triglycerides. Moreover, with respect to the fibrates, various adverse effects such as gastrointestinal injury, anthema, headache, hepatic disorder, renal disorder and biliary calculus are reported. The reason is considered to be due to that the fibrates exhibit extensive pharmacological function.

On the other hand, it is ascertained that the major intracellular target protein of Troglitazone, Pioglitazone and Rosiglitazone being a series of thiazolidine-2,4-dione derivatives that are therapeutic drugs for type II diabetes (noninsulin-dependent diabetes) and exhibit blood glucose-decreasing action, improving action on hyperinsulinemia, etc. is PPAR $\gamma$ , and these drugs increase the transactivation of PPAR $\gamma$  (Endocrinology, 1996, 137, 4189, Cell., 1995, 83, 803, Cell., 1995, 83, 813). Hence, PPAR $\gamma$ -activator (agonist) that can

1049937.022002

augment the transactivation of PPAR $\gamma$  is important as antidiabetic drug.

As described, when considering the roles of transcription factor called PPAR on the function on adipocytes and the controlling mechanisms of glucose metabolism and lipid metabolism, if a compound that binds directly to as a ligand of PPAR, in particular, human PPAR and can activate human PPAR could be created, it would be reasonable to expect the medicinal use as a compound that exhibits blood glucose-decreasing action and/or decreasing action of lipids (both of cholesterol and triglyceride) in blood due to very specific mechanism.

For compounds having an affinity to PPAR $\alpha$  as ligands of PPAR $\alpha$ , HEPE (hydroxyeicosapentaenoic acid) produced via oxidation with cytochrome P-450 and eicosanoids in HETE (hydroxyeicosatetraenoic acid) groups, in particular, 8-HETE, 8-HEPE, etc. are reported in addition to LTB $_4$ , being a metabolite of arachidonic acid (Proc. Natl. Acad. Sci., 1997, 94, 312). However, these endogenous unsaturated fatty acid derivatives are unstable metabolically and chemically and cannot be offered as medicinal drugs.

Moreover, with Troglitazone, the occurrence of serious adverse effect on liver is reported rarely, hence the development of a therapeutic drug for type II diabetes with effectiveness and high safety is being sought.

Now, as compounds with similar structure to the inventive substituted benzylthiazolidine-2,4-dione derivatives, thiazolidine-2,4-dione derivatives in Japanese Unexamined Patent Publication Nos. Sho 55-22636, Sho 60-51189, Sho 61-85372, Sho 61-286376, Hei 1-131169, Hei 2-83384, Hei 5-213913, Hei 8-333355, Hei 9-48771 and Hei 9-169746, European Patent

Open No. 0441605, WO-92/07839, etc. are known. However, all of these compounds are thiazolidine-2,4-dione derivatives with different structure from the inventive compounds.


With regard to patents etc. reporting the agonistic effect on PPAR  $\alpha$ , WO-97/25042, WO-97/36579, etc. are reported, but all of these have different structure from the inventive compounds and the transactivation function of PPAR $\alpha$  is also never satisfied in strength.

Both the hyperlipidemia and the diabetes are risk factors of arterosclerosis and, from a viewpoint of the prevention of arterosclerosis, in particular, coronary arterosclerosis, the development of a therapeutic drug for metabolic diseases with effectiveness and high safety is desired clinically.

#### Disclosure of the invention

As a result of diligent studies paying an attention to such specific roles on the lipid metabolism of human PPAR, differentiation of adipocytes, etc. aiming at the creation of structurally novel drug with effectiveness and high safety as a therapeutic drug for metabolic diseases, the inventors have found that novel substituted benzylthiazolidine-2,4-dione derivatives represented by the following general formula (1) have excellent transactivation function of human PPAR, and exhibit the blood glucose-decreasing action and the lipid-decreasing action, leading to the completion of the invention.


Namely, the invention relates to the substituted benzylthiazolidine-2,4-dione derivatives represented by the general formula (1)



[wherein  $R^1$  denotes a chlorine atom, bromine atom, nitro group, trifluoromethoxy group, ethoxy group, propoxy group or isopropoxy group, and  $R^2$  denotes a hydrogen atom or chlorine atom], their medicinally acceptable salts and their hydrates.


The salts of the compounds represented by the general formula (1) in the invention are of common use and metal salts, for example, alkali metal salts (e.g. sodium salt, potassium salt, etc.), alkaline earth metal salts (e.g. calcium salt, magnesium salt, etc.), aluminum salt, and other pharmacologically acceptable salts are mentioned.

Furthermore, for the compounds represented by the general formula (1), the existence of various tautomers is considered. These are, for example, as shown in the following formulae.




[wherein  $R^1$  denotes a chlorine atom, bromine atom, nitro group, trifluoromethoxy group, ethoxy group, propoxy group or isopropoxy group, and  $R^2$  denotes a hydrogen atom or chlorine atom]. In the general formula (1) aforementioned, all of these isomers and their mixtures are to be included in the scope of this invention.

According to the invention, the compounds being said the general formula (1) can be prepared, for example, through the following process (Scheme 1).



Scheme 1

Namely, the compounds represented by the general formula (1) can be prepared by reacting (first process) publicly known (Japanese Unexamined Patent Publication No. Hei 8-333355) compound (2) and the compounds represented by the general formula (3)



[wherein  $R^1$  denotes a chlorine atom, bromine atom, nitro group, trifluoromethoxy group, ethoxy group, propoxy group or



isopropoxy group, and  $R^2$  denotes a hydrogen atom or chlorine atom].

The first process can be performed by the leaving carboxyl group as it is, or converting it to the reactive derivative.

As the "reactive derivative group of the carboxyl group", acid chloride, acid bromide, acid anhydride, carbonylimidazole or the like can be mentioned. In the case of the reaction using the reactive derivative, the reaction can be performed in a solvent such as methylene chloride, chloroform, dioxane or N,N-dimethylformamide in the presence or absence of, for example, alkali metal hydride such as sodium hydride, alkali metal hydroxide such as sodium hydroxide, alkali metal carbonate such as potassium carbonate, or organic base such as pyridine or triethylamine as a base.

In the case of conducting the reaction by leaving the carboxylic acid as it is, the reaction can be performed in a solvent such as methylene chloride, chloroform, dioxane or N,N-dimethylformamide in the presence of condensing agent in the presence or absence of base, in the presence or absence of additive.

As the condensing agent, for example, dicyclohexylcarbodiimide, 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride, diethyl cyanophosphate, diphenylphosphoric azide, carbonyldiimidazole or the like can be mentioned. As the base, for example, alkali metal hydroxide such as sodium hydroxide, alkali metal carbonate such as potassium carbonate, or organic base such as pyridine or triethylamine can be mentioned. As the additive, N-hydroxybenzotriazole, N-hydroxysuccinimide, 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazine or the like can be mentioned. The reaction can

be performed at a reaction temperature of -20°C to 100°C, preferably at 0°C to 50°C.

As the administering form of the novel compounds of the invention, for example, oral administration with tablet, capsule, granule, powder, inhalant, syrup or the like, or parenteral administration with injection, suppository or the like can be mentioned.

Best embodiment to put the invention into practice

In following, the invention will be illustrated based on concrete examples, but the invention is not confined to these examples.

(Example 1)

N-[(4-Nitrophenyl)methyl]-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxybenzamide

5-[(2,4-Dioxothiazolidin-5-yl)methyl]-2-methoxybenzoic acid (422 mg, 1.50mmol), triethylamine (0.732mL, 5.25mmol) and methylene chloride (7mL) were mixed and ethyl chlorocarbonate (0.158mL, 1.50 mmol) was added under cooling with ice and stirring. After stirring for 10 minutes under cooling with ice, 4-nitrobenzylamine (283mg, 1.50mmol) was added. The mixture was stirred for 2 hours at room temperature, and then allowed to stand overnight. After washed with water, the reaction mixture was dried over anhydrous sodium sulfate and concentrated. The residue was dissolved into water (20mL), which was made acidic with 10% hydrochloric acid and stirred for 2 hours. The precipitated crystals were collected by filtration, washed with water and dried, then they were recrystallized from ethanol to obtain 472mg (75%) of the title compound as pale yellow prisms.  
Melting point 236.5-238.5°C;

Mass analysis  $m/z$  415( $M^+$ );

Elemental analysis(%)  $C_{16}H_{17}N_3O_6S$ :


Calcd.(%) C, 54.93; H, 4.12; N, 10.12.

Found (%) C, 54.84; H, 4.14; N, 9.98.

(Examples 2 through 9)

Similarly to Example 1, the compounds shown in Table 1 were obtained.

(Table 1)



Ex- ample	R <sup>1</sup>	R <sup>2</sup>	Melting point (°C)	Charac. formula		Elemental analysis (%)			
2	4-Br	H	198.0-200.0	$C_{15}H_{17}BrN_3O_4S$	Calcd.;	C 50.79,	H 3.81,	N 6.23	
					Found;	C 50.75,	H 3.75,	N 6.16	
3	4-Cl	H	199.0-201.0	$C_{15}H_{17}ClN_3O_4S$	Calcd.;	C 56.36,	H 4.23,	N 6.92	
					Found;	C 56.27,	H 4.24,	N 6.82	
4	3-CF <sub>3</sub> O	H	Amorphous	$C_{20}H_{17}F_3N_3O_5S$	Calcd.;	C 52.86,	H 3.77,	N 6.16	
					Found;	C 52.82,	H 3.75,	N 6.08	
5	4-EtO	H	130.0-132.0	$C_{21}H_{22}N_3O_5S$	Calcd.;	C 60.85,	H 5.35,	N 6.76	
					Found;	C 60.87,	H 5.30,	N 6.73	
6	4-iPrO	H	79.0-81.5	$C_{22}H_{24}N_3O_5S$	Calcd.;	C 59.18,	H 5.87,	N 6.27	
				$\cdot H_2O$	Found;	C 59.27,	H 5.74,	N 6.28	
7	4-nPrO	H	132.0-133.0	$C_{22}H_{24}N_3O_5S$	Calcd.;	C 61.15,	H 5.69,	N 6.48	
				$\cdot 1/5H_2O$	Found;	C 61.03,	H 5.51,	N 6.37	
8	4-Cl	2-Cl	188.0-189.0	$C_{15}H_{16}Cl_2N_3O_4S$	Calcd.;	C 51.52,	H 3.73,	N 6.32	
				$\cdot 1/5H_2O$	Found;	C 51.63,	H 3.60,	N 6.29	
9	4-Cl	3-Cl	181.0-182.0	$C_{15}H_{16}Cl_2N_3O_4S$	Calcd.;	C 51.52,	H 3.73,	N 6.32	
				$\cdot 1/5H_2O$	Found;	C 51.45,	H 3.55,	N 6.30	

<Biological activity>

(Test example 1)

Test of transactivation on peroxisome proliferator-  
activated receptors  $\alpha$  and  $\gamma$

To CHO cells cultured in a Ham's F-12 medium containing

10049937 022002

fatty acid free 10% fetal calf serum, receptor plasmid and its reporter plasmid (STRATAGENE Corp.) that express fused protein of DNA-binding domain being transcription factor of yeast with ligand-binding domain of human type PPARs  $\alpha$  and  $\gamma$  (Biochemistry, 1993, 32, 5598), and  $\beta$ -galactosidase plasmid (Promega Corp.) for internal standard were cotransfected with lipofectamine in the serum-free state. Thereafter, testing compound and control compound (Troglitazone or Pioglitazone for control drug of PPAR  $\gamma$ , and (8S)-HETE for control drug of PPAR  $\alpha$ ) were dissolved into DMSO and adjusted with Ham's F-12 medium containing fatty acid free 10% fetal calf serum, so that the final concentration of DMSO became 0.01% to culture. After 24 hours, CAT activity and  $\beta$ -galactosidase activity were measured.

Results are shown in Table 2. From these results, it was shown that the inventive compounds had potent transactivation action on human peroxisome proliferator-activated receptors  $\alpha$  and  $\gamma$ .

(Table 2)		Transactivation	
Example	EC <sub>50</sub>		
	PPAR $\alpha$	PPAR $\gamma$	
	EC <sub>50</sub> ( $\mu$ mol/L)	EC <sub>50</sub> ( $\mu$ mol/L)	
1	0.53	1.6	
2	0.49	0.29	
3	0.26	0.40	
4	0.18	0.36	
5	0.43	0.30	
6	0.76	0.11	
7	0.11	1.8	
8	0.22	0.28	
9	0.70	1.1	
Troglitazone	-	1.15	
Pioglitazone	-	0.72	
(8S)-HETE	1.30	-	


#### Utilizability in the industry

From the results as described above, the inventive substituted benzylthiazolidine-2,4-dione derivatives are novel compounds with excellent human PPAR transactivation.

From the fact that these inventive compounds have agonistic activity on human PPAR, it can be said that they are effective compounds as blood glucose-decreasing drugs and therapeutic drugs for hyperlipidemia aforementioned.

# SCOPE OF THE CLAIM

1. Substituted benzylthiazolidine-2,4-dione derivatives represented by a general formula (1)




- [wherein  $R^1$  denotes a chlorine atom, bromine atom, nitro group, trifluoromethoxy group, ethoxy group, propoxy group or isopropoxy group, and  $R^2$  denotes a hydrogen atom or chlorine atom], their medicinally acceptable salts and their hydrates.
2. The substituted benzylthiazolidine-2,4-dione derivatives, their medicinally acceptable salts and their hydrates of Claim 1, wherein  $R^1$  is trifluoromethoxy group.
  3. The substituted benzylthiazolidine-2,4-dione derivatives, their medicinally acceptable salts and their hydrates of Claim 1, wherein  $R^1$  is ethoxy group.
  4. The substituted benzylthiazolidine-2,4-dione derivatives, their medicinally acceptable salts and their hydrates of Claim 1, wherein  $R^1$  is chlorine atom.
  5. The substituted benzylthiazolidine-2,4-dione derivatives, their medicinally acceptable salts and their hydrates of Claim 1, wherein  $R^1$  and  $R^2$  are chlorine atoms.
  6. A compound of Claim 1, being N-[(3-trifluoromethoxyphenyl)methyl]-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxybenzamide, its medicinally acceptable salts and its hydrates.

7. A compound of Claim 1, being N-[(4-ethoxyphenyl)methyl]-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxybenzamide, its medicinally acceptable salts and its hydrates.

8. A compound of Claim 1, being N-[(4-chlorophenyl)methyl]-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxybenzamide, its medicinally acceptable salts and its hydrates.


9. A compound of Claim 1, being N-[(2,4-dichlorophenyl)methyl]-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxybenzamide, its medicinally acceptable salts and its hydrates.

10. A blood glucose-decreasing drug having at least one or more kinds of substituted benzylthiazolidine-2,4-dione derivatives represented by the general formula (1)




[wherein R<sup>1</sup> denotes a chlorine atom, bromine atom, nitro group, trifluoromethoxy group, ethoxy group, propoxy group or isopropoxy group, and R<sup>2</sup> denotes a hydrogen atom or chlorine atom], their medicinally acceptable salts and their hydrates as effective ingredients.

11. Antihyperlipidemic drug having at least one or more kinds of substituted benzylthiazolidine-2,4-dione derivatives represented by the general formula (1)



[wherein  $R^1$  denotes a chlorine atom, bromine atom, nitro group, trifluoromethoxy group, ethoxy group, propoxy group or isopropoxy group, and  $R^2$  denotes a hydrogen atom or chlorine atom], their medicinally acceptable salts and their hydrates as effective ingredients.

12. An agonist drug of human peroxisome proliferator-activated receptor having at least one or more kinds of substituted benzylthiazolidine-2,4-dione derivatives represented by a general formula (1)




[wherein  $R^1$  denotes a chlorine atom, bromine atom, nitro group, trifluoromethoxy group, ethoxy group, propoxy group or isopropoxy group, and  $R^2$  denotes a hydrogen atom or chlorine atom], their medicinally acceptable salts and their hydrates as effective ingredients.



# SUMMARY

The invention provides novel substituted benzylthiazolidine-2,4-dione derivatives which increase the transactivation of receptor as a ligand of human peroxisome proliferator-activated receptor (PPAR) and exhibit the blood glucose-decreasing action and lipid-decreasing action, and a process for preparing them.

The invention relates to substituted benzylthiazolidine-2,4-dione derivatives represented by a general formula (1)



[wherein R<sup>1</sup> denotes a chlorine atom, bromine atom, nitro group, trifluoromethoxy group, ethoxy group, propoxy group or isopropoxy group, and R<sup>2</sup> denotes a hydrogen atom or chlorine atom], their medicinally acceptable salts, their hydrates and a process for preparing them.

## Declaration, Power Of Attorney and Petition

Page 1 of 3

WE (I) the undersigned inventor(s), hereby declare(s) that:

My residence, post office address and citizenship are as stated below next to my name,

We (I) believe that we are (I am) the original, first, and joint (sole) inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled

Substituted benzylthiazolidine-2,4-dione derivatives

the specification of which

☒ is attached hereto.

☐ was filed on \_\_\_\_\_ as

Application Serial No. \_\_\_\_\_

and amended on \_\_\_\_\_.

☒ was filed as PCT international application

Number PCT/JP00/05522

on August 18, 2000,

and was amended under PCT Article 19

on \_\_\_\_\_ (if applicable).

We (I) hereby state that we (I) have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

We (I) acknowledge the duty to disclose information known to be material to the patentability of this application as defined in Section 1.56 of Title 37 Code of Federal Regulations.

We (I) hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed. Prior Foreign Application(s)

Application No.	Country	Day/Month/Year	Priority Claimed
Hei 11-235530	Japan	23/08/1999	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No



3-00  
Koji Murakami  
NAME OF SECOND JOINT INVENTOR

Koji Murakami  
Signature of Inventor

January 22, 2002  
Date

3-00  
Masaki Tsunoda  
NAME OF THIRD JOINT INVENTOR

Masaki Tsunoda  
Signature of Inventor

January 22, 2002  
Date

4-00  
Yukie Takahashi  
NAME OF FOURTH JOINT INVENTOR

Yukie Takahashi  
Signature of Inventor

January 22, 2002  
Date

NAME OF FIFTH JOINT INVENTOR

Signature of Inventor

Date

Residence: 356-1, Mamada, Oyama-shi,  
TOCHIGI 329-0205 JAPAN Jpy

Citizen of: Japan

Post Office Address: Same as residence

Residence: Riverside-maison 201,  
2-2-2, Kasukabe-higashi,

Kasukabe-shi, SAITAMA 344-0062 Jpy  
JAPAN

Citizen of: Japan

Post Office Address: Same as residence

Residence: 5982-1, Tomonuma, Nogi-  
machi, Shimotsuga-gun, TOCHIGI Jpy  
329-0101 JAPAN

Citizen of: Japan

Post Office Address: Same as residence

Residence: \_\_\_\_\_

Citizen of: \_\_\_\_\_

Post Office Address: \_\_\_\_\_